Clinical trials: Stage III Skin Cancer
Melanoma Stage III, Melanoma Stage IV
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
- Trial name
- NCT04741997
- Testing
- Encorafenib Pill, Binimetinib Pill, Nivolumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Hot Flashes
Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial
RATIONALE: Gathering information about the frequency and intensity of hot flashes in patients with breast cancer and in patients who have a high risk of developing breast cancer may help doctors learn more about menopausal…
- Trial name
- NCT00666913
- Testing
- informational intervention
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants…
- Trial name
- IPATunity130 (NCT03337724)
- Testing
- Ipatasertib, Paclitaxel
- Where
- 176 sites in United States, Argentina and 28 more
- Volunteers
- 579 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast…
- Trial name
- NEST (NCT01622361)
- Testing
- Adriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Asan Medical Center
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body.
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT00376688
- Testing
- Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Acral Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
This is a prospective, multicenter, open-label, 1:1 randomized phase II trial enrolling 76 patients with AJCC stage III surgically resectable acral melanoma.
- Trial name
- NCT07854522
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus)
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma, Complication
Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients
This prospective randomized non-inferiority study is designed to compare the rate and severity of complications after axillary and inguinal lymph node dissection in stage III melanoma patients in a study group where the drain is…
- Trial name
- NCT04680182
- Testing
- Suction drain
- Where
- Norway
- Volunteers
- 104 people
- Sponsor
- Oslo University Hospital
Melanoma
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- COMBI-AD (NCT01682083)
- Testing
- Dabrafenib, Trametinib
- Where
- 168 sites in United States, Argentina and 23 more
- Volunteers
- 870 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer
MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer
RATIONALE: Diagnostic procedures such as MRI scans may help predict early response to treatment in patients with breast cancer undergoing chemotherapy.
- Trial name
- NCT00978770
- Testing
- systemic chemotherapy, diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Cancer Clinical Trials Unit, Scotland
Breast Cancer
Study of Nab-Paclitaxel in High Risk Early Breast Cancer
two-armed trial to compare E-nP-C against tailored dtEC-dtD in patients with high risk early breast cancer
- Trial name
- GAIN-2 (NCT01690702)
- Testing
- Epirubicin, nab-Paclitaxel, Cyclophosphamide
- Where
- Germany
- Volunteers
- 2,886 people
- Sponsor
- GBG Forschungs GmbH
Arthralgia, Breast Cancer
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Trial name
- NCT01385137
- Testing
- omega-3 fatty acid
- Where
- 292 sites in United States
- Volunteers
- 262 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00722072
- Testing
- fulvestrant, sorafenib tosylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8
- Trial name
- DIET (NCT04645680)
- Testing
- Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
European Celecoxib Trial in Primary Breast Cancer
It has been found that the chemical changes that take place in a patient's body during the development of inflammation may provide an environment which stimulates cancer cells.
- Trial name
- REACT (NCT02429427)
- Testing
- Celecoxib
- Volunteers
- 2,639 people
- Sponsor
- Imperial College London
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)
Pre-operative chemotherapy in operable breast cancer, phase III study comparing a short intensive pre-operative chemotherapy with the same therapy initiated shortly after surgery (peri-operatively) (POCOB) (EORTC 10902)
- Trial name
- NCT00544505
- Testing
- Fluorouracil/Epirubicin/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer
S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether mastectomy, chemotherapy, and/or hormone therapy are more effective with or without radiation therapy in treating breast…
- Trial name
- NCT00005983
- Testing
- radiation therapy, surgery
- Where
- Canada
- Volunteers
- 98 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Gastric Cancer
Biological Therapy in Treating Patients With Advanced Cancer
RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT00005956
- Testing
- HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.